References
Alivernini S, Pugliese D, Tolusso B, et al. Paradoxical arthritis occurring during anti-TNF in patients with inflammatory bowel disease: histological and immunological features of a complex synovitis. RMD Open 2018;4:e000667.
Takahashi T, Asano Y, Shibata S, et al. Arthritis possibly induced and exacerbated by a tumour necrosis factor antagonist in a patient with psoriasis vulgaris. Br J Dermatol 2015; 172: 1458–60.
Nakamura K, Asano Y, Shibata S, et al. Case of psoriasis vulgaris developing ulcerative colitis during adalimumab treatment. J Dermatol 2015; 42: 1029–30.
Pietrzak D, Pietrzak A, Krasowska D, et al. Digestive system in psoriasis: an update. Arch Dermatol Res 2017; 309: 679–93.
Toussirot E, Houvenagel E, Goeb V, et al. Development of inflammatory bowel disease during anti-TNF-a therapy for inflammatory rheumatic disease: a nationwide series. Joint Bone Spine 2012; 79: 457–63.
Toussirot E, Charollais R, Aubin F. Multiple paradoxical adverse events in a patient with ankylosing spondylitis treated with adalimumab. Eur J Dermatol 2016; 26: 406–8.
Toussirot E, Aubin F. Paradoxical reactions under TNF-α blocking agents and other biological agents given for chronic immune-mediated diseases: an analytical and comprehensive overview. RMD Open 2016; 2: e000239.
Makino Y, Tanaka H, Nakamura K, Fujita M, Akiyama K, Makino I. Arthritis in a patient with psoriasis after interferon-α therapy for chronic hepatitis C. J Rheumatol 1994; 21: 1771–2.
Mitoro A, Yoshikawa M, Yamamoto K, et al. Exacerbation of ulcerative colitis during α-interferon therapy for chronic hepatitis C. Intern Med 1993; 32: 327–31.
Watanabe T, Inoue M, Harada K, et al. A case of exacerbation of ulcerative colitis induced by combination therapy with PEG-interferon a-2β and ribavirin. Gut 2006; 55: 1682–3.
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Disclosure. Financial support: none. Conflicts of interest: none.
About this article
Cite this article
Toyama, S., Kanda, H., Tateishi, S. et al. A case of concurrent psoriasis and ulcerative colitis with development of arthritis during adalimumab treatment. Eur J Dermatol 29, 651–653 (2019). https://doi.org/10.1684/ejd.2019.3657
Published:
Issue Date:
DOI: https://doi.org/10.1684/ejd.2019.3657